Over the last several years, drugmakers have agreed to pay $57 billion in opioid settlements, including a landmark $26 ...

Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...

She has resigned from the former; the latter does not matter since 23andMe’s equity could be wiped out. If persistence pays off, a company that started out as little more than an intriguing idea and a ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes ...

will combine their branded drugs businesses that include Endo's testosterone injection Aveed as well as Mallinckrodt's Acthar Gel and kidney disease therapy Terlivaz. Advt The merger will "create ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal ... Read more about Endo locking into a merger agreement in the Philadelphia Business Journal.

We will always give you the option to opt out of our marketing. Wachtell Lipton Rosen & Katz and Davis Polk & Wardwell have scored lead roles on the $6.7bn merger of drugmakers Mallinckrodt and Endo.

In addition, Endo has entered into an agreement to sell the international pharmaceutical business to Knight Therapeutics Inc. for $99 million. The deal will reduce costs and expand access to new ...

Mallinckrodt plc and Endo, Inc. announced that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals leader.

Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and US opioid litigation, have agreed to merge in a deal valued at nearly $7 billion. Endo shareholders will get $80 ...

DUBLIN and MALVERN, Pa. - Mallinckrodt plc and Endo International plc announced a definitive merger agreement in a stock and cash transaction. The deal is set to create a global pharmaceuticals leader ...